PEPVENDORS
Peptides/TB-500

For Research Purposes Only. This page summarizes published preclinical and clinical research. It does not constitute medical advice and is not a recommendation for human use. Always consult a qualified healthcare professional.

Tissue Repair

TB-500

Synthetic fragment of Thymosin Beta-4. Studied for wound healing, muscle and tendon repair, angiogenesis, and anti-inflammatory activity.

Class
Thymosin Beta-4 fragment
Sequence
LKKTETQ (7 amino acids)
Trial Status
Preclinical (fragment)
Parent Compound
Phase I/II (Tβ4)

Overview

TB-500 is a synthetic peptide derived from Thymosin Beta-4 (Tβ4), a 43-amino-acid protein present in virtually all nucleated human and animal cells. The TB-500 sequence — LKKTETQ, corresponding to residues 17–23 of Tβ4 — was identified in the 1990s as the actin-binding domain responsible for the majority of Tβ4's biological activity. By isolating this fragment, researchers created a shorter, more accessible compound that retains the key functional properties of the parent protein while being simpler to synthesize.

The central biological role of Tβ4 and its TB-500 fragment is regulation of actin polymerization. Actin filaments are the structural backbone of the cytoskeleton and are essential for cell motility, division, and the migratory response that initiates wound healing. By sequestering globular actin (G-actin) monomers, TB-500 maintains a pool of available actin for rapid filament assembly, facilitating the migration of repair cells — fibroblasts, keratinocytes, and endothelial cells — into injured tissue. This mechanism underpins the angiogenic and anti-inflammatory effects observed across multiple animal models.

RegeneRx Biopharmaceuticals has been the primary clinical developer of full-length Tβ4, conducting Phase I and Phase II trials for acute myocardial infarction (REVEAL trial, NCT01311518) and dry eye syndrome. These trials established a human safety profile for the parent compound, which has informed the broader research interest in TB-500. The isolated TB-500 fragment has not been the subject of formal human clinical trials. Most published research on TB-500 specifically remains in rodent and in vitro models.

Research Status

FDA Status
TB-500 (the fragment) is not FDA-approved. Parent compound Thymosin Beta-4 has been studied in FDA-cleared Phase I and Phase II human trials by RegeneRx for cardiac and ocular indications, establishing a safety profile for the parent protein.
Trial Phase
TB-500 fragment: preclinical only. Thymosin Beta-4 (parent): Phase I/II completed. Phase III not initiated as of early 2026.
Key Studies

Smart et al. (2007, Annals of the New York Academy of Sciences) demonstrated cardiac repair effects of Tβ4 in infarct models. RegeneRx REVEAL trial (Phase II, NCT01311518) investigated Tβ4 in acute MI. Goldstein and Kleinman have published extensively on Tβ4 mechanisms in wound healing models. TB-500 fragment-specific studies appear in Annals of the New York Academy of Sciences and related journals.

Common Research Protocols

Loading phase (community-reported)2–5mg, twice per week for 4–6 weeks
Maintenance phase2–5mg once or twice monthly
Administration routes studiedSubcutaneous or intramuscular injection
Typical vial sizes available2mg, 5mg, 10mg
Reconstitution solventBacteriostatic water
Common stackingOften combined with BPC-157 (complementary mechanisms; together sold as GLOW or KLOW blends)

Dose ranges are extrapolated from published animal research and community protocols. No validated human dosing exists for TB-500. This is for educational reference only and is not a recommendation for human use.

Use the reconstitution calculator →

Storage & Handling

Store lyophilized TB-500 at −20°C. Once reconstituted with bacteriostatic water, store at 4°C and use within 28–30 days. Avoid prolonged exposure to room temperature or direct light.

What to Look for When Buying

TB-500 is a moderately complex peptide to synthesize correctly. Independent HPLC purity verification from a third-party lab (such as Finnrick Analytics) is especially important for this compound.

Verify the compound is sold as TB-500 (the LKKTETQ fragment), not as full-length Thymosin Beta-4. While related, they are different molecules and are priced and dosed differently.

Quantity accuracy matters: check whether the vendor has been tested for fill accuracy, not just purity. A nominally 5mg vial that contains 3mg of active compound is a significant underperformance.

TB-500 is frequently sold alongside or in blends with BPC-157 (e.g., GLOW, KLOW stacks). If buying a blend, confirm the stated ratios of each component are independently verified.

COAs should specify HPLC purity, not just mass spectrometry identity confirmation. Identity confirmation alone does not verify the concentration of active compound.

Compare Vendor Pricing

PepVendors tracks live pricing for TB-500 across multiple vendors, updated weekly. Compare price per mg, available sizes, and purity data side by side.

Compare TB-500 prices →

Third-Party Purity Data

Full data at finnrick.com →

Independent HPLC test results from Finnrick Analytics. Purity values are averages across multiple samples. Check the Finnrick vendor page for batch-level detail.

VendorPurity
Verified Peptides
98.8%A
Pure Rawz
97.8%B
Related Peptides
BPC-157CJC-1295 + Ipamorelin
Legal Disclaimer

For Research Purposes Only — Not Medical Advice. The information on this page is compiled from published peer-reviewed research, publicly available clinical trial data, and independent third-party testing results. It is intended solely as an educational reference for researchers.

Nothing on this page constitutes medical advice, a diagnosis, or a treatment recommendation. Peptides listed as research chemicals are not approved for human consumption unless explicitly noted as FDA-approved pharmaceuticals. PepVendors is a price comparison and information platform — we do not manufacture, sell, or distribute any compounds. Always consult a qualified and licensed healthcare professional before considering any compound for personal use.